Matthew Stanton, CFA
Stock Analyst at Jefferies
(0.62)
# 3,972
Out of 4,457 analysts
21
Total ratings
42.9%
Success rate
-15.2%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton, CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintained: Hold | $9.5 → $13 | $16.28 | -20.12% | 6 | Jun 8, 2026 | |
| RGEN Repligen | Maintained: Hold | $135 → $142 | $137.00 | +3.65% | 7 | May 5, 2026 | |
| AZTA Azenta | Maintained: Buy | $42 → $35 | $25.51 | +37.20% | 5 | Apr 1, 2026 | |
| MRVI Maravai LifeSciences Holdings | Maintained: Buy | $10 | $6.39 | n/a | 1 | Mar 18, 2025 | |
| LAB Standard BioTools | Initiated Coverage: Buy | $3.25 | $0.7474 | n/a | 1 | Apr 4, 2024 | |
| BLFS BioLife Solutions | Initiated Coverage: Buy | $22 | $28.30 | n/a | 1 | Apr 4, 2024 |
Cryoport
Jun 8, 2026
Maintained: Hold
Price Target: $9.5 → $13
Current: $16.28
Upside: -20.12%
Repligen
May 5, 2026
Maintained: Hold
Price Target: $135 → $142
Current: $137.00
Upside: +3.65%
Azenta
Apr 1, 2026
Maintained: Buy
Price Target: $42 → $35
Current: $25.51
Upside: +37.20%
Maravai LifeSciences Holdings
Mar 18, 2025
Maintained: Buy
Price Target: $10
Current: $6.39
Upside: n/a
Standard BioTools
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $3.25
Current: $0.7474
Upside: n/a
BioLife Solutions
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $22
Current: $28.30
Upside: n/a